Related Experiment Video
Updated: May 4, 2026
Standardized Histomorphometric Evaluation of Osteoarthritis in a Surgical Mouse Model
Published on: May 6, 2020
Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: a systematic review
Srijit Das, Rajalingham Sakthiswary1
1Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia. sakthis5@hotmail.com.
Abstract:
Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub- Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.
Insights
Sclerostin-neutralizing monoclonal antibodies (Scl-Ab) show promise in preventing osteoporotic fractures. These antibodies improve bone density, volume, and thickness, offering a new avenue for osteoporosis treatment.
Area of Science:
- Bone biology and osteoporosis research.
- Pharmacological interventions for bone diseases.
Background:
- Osteoporotic fractures cause significant morbidity and healthcare costs.
- Sclerostin, a protein inhibiting bone formation, is a key target for osteoporosis therapy.
Purpose of the Study:
- To systematically review murine studies on sclerostin-neutralizing monoclonal antibodies (Scl-Ab).
- To evaluate the effects of Scl-Ab on bone metabolism and histomorphometric parameters.
Main Methods:
- Systematic literature search across major scientific databases (BIOSIS, Cinahl, EMBASE, PubMed, Web of Science, Cochrane Library).
- Analysis of published murine studies investigating Scl-Ab effects on bone.
Main Results:
- Scl-Ab administration was significantly associated with improved bone formation.
- Key improvements observed include increased bone density, bone volume, and trabecular thickness.
- Positive effects on bone homeostasis were noted in rodent models.
Conclusions:
- Scl-Ab demonstrates potential as an effective anti-osteoporotic agent.
- Targeting sclerostin with monoclonal antibodies offers a promising therapeutic strategy for osteoporosis.
- Further research into Scl-Ab efficacy and safety is warranted.
